Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA7 | P43166 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14409745 | 0.87 | TSHR (0.50) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL4625850 | 0.86 | TSHR (0.61) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL16302043 | 0.81 | TSHR (0.61) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL23767907 | 0.80 | CA12 (0.56) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL277628 | 0.80 | TSHR (0.47) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL23817414 | 0.80 | TSHR (0.40) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL1852703 | 0.78 | TSHR (0.53) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL14048740 | 0.78 | TSHR (0.53) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL28039456 | 0.78 | TSHR (0.53) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL28639005 | 0.78 | TSHR (0.45) | TSHRCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9005670-B2 | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130142887-A1 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2011085039-A2 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142887-A1 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | EP300, HDAC1, KAT2A | TSHR 3344/4885CA12 1423/4885CA1 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.